Opinion|Videos|November 20, 2025
Using TDMs to Improve Care and Communication
Author(s)Jonathan M. Meyer, MD, DLFAPA
Reviewing TDM’s evidence-based rationale, its clinical utility, and connection to outcomes.
Advertisement
This video covers the following questions:
- Can you walk us through the typical therapeutic range—and what factors can influence individual variability?
- How can TDM help clinicians differentiate between treatment resistance due to pharmacokinetic factors (like metabolism) versus true nonresponse? and What role does TDM play in preventing toxicity, including dose-related adverse effects such as seizures or sedation?
- How might TDM support patient adherence and shared decision-making in clinical practice?
Advertisement
Related to this article
In this case exploration, a teen survives a gun injury yet denies self-harm, pushing clinicians to read beyond words and plan safety when suicide intent is unclear.
How tuning body signals with closed-loop sound and chill tech may ease dissociation and anhedonia, offering drug-free add-ons to therapy.
Two grief experts expose the hidden health, social, and economic toll of bereavement—and the policy gaps leaving millions of grieving Americans unsupported.
Learn how the inhibition constant and 5-HT2A binding explain LSD effects—and why potent atypical antipsychotics may rapidly end a bad trip.
FDA hearing spotlights debates over psychedelic therapy: who administers, how to prove efficacy, and how to track safety as approvals near.
New US adult ADHD guidance nears publication, promising clearer diagnosis, comorbidity screening, and clinician training to curb misdiagnosis.
New research maps an mPFC–zona incerta circuit that drives punishment-resistant binge eating and hints at personalized brain stimulation targets for better treatment.
Phase 3 BLOOM tests 48-hour at-home oral brexanolone for rapid postpartum depression relief, with tighter monitoring after prior trial issues.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Vol 43, Issue 9 - Interactive
2
FDA Hearing on Psychedelic Medicine Reveals a Field Divided on the Road to Approval
3
Debunking the Top 10 Misleading Claims About Antidepressants
4
New Adult ADHD Guidelines: What Resources Are Coming Soon
5